Enhancing Hepatic MBOAT7 Expression Does Not Improve Nonalcoholic Steatohepatitis in Mice

Background & Aims Genetic analyses of human NASH have revealed polymorphisms near the membrane bound O-acyl transferase domain containing 7 (MBOAT7) gene associated with worsened liver injury. NAFLD/NASH also appears to decrease MBOAT7 expression or activity independent of these polymorphisms. Thus, we hypothesized that enhancing MBOAT7 function in NASH would improve pathology. Approach & Results Male C57BL6/J mice were infected with adeno-associated virus 8 (AAV8) expressing MBOAT7 under control of the hepatocyte-specific thyroid hormone-binding globulin promoter, or control virus expressing green fluorescent protein (GFP). Mice were infected after NASH induction with either choline-deficient high-fat diet or Gubra Amylin NASH diet and compared to low-fat fed control mice. Both NASH diets increased liver weights, liver triglycerides, and plasma alanine and aspartate aminotransferase (ALT and AST) markers of liver injury, which were modestly yet significantly improved by MBOAT7 overexpression. However, NASH liver histology assessed by categorical scoring was not substantially improved by MBOAT7 overexpression. MBOAT7 regulates the formation of phosphatidylinositol (PI) predominantly by arachidonoylation of lysophosphatidylinositol (LPI). Shotgun lipidomics of NASH GFP-control livers suggested decreased MBOAT7 activity in that LPI content was elevated, and both total and arachidonoylated-PI were reduced. Surprisingly, MBOAT7 overexpression did not rescue the content of most arachidonoylated PI species but did normalize or increase the abundance of several oleate and linoleate-containing PI species. Free arachidonic acid was elevated but the MBOAT7 substrate arachidonoyl-CoA was found to be low in all NASH livers compared to low-fat fed mice, likely due to decreased expression of both long-chain acyl-CoA synthetases (ACSL) 1 and 4 in NASH livers compared to controls. Conclusions These results suggest MBOAT7 overexpression fails to measurably improve NASH pathology potentially due to insufficient abundance of its arachidonoyl-CoA substrate in fatty livers.

[1]  M. Orho-Melander,et al.  Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease , 2021, Journal of hepatology.

[2]  M. Longo,et al.  Genetics Is of the Essence to Face NAFLD , 2021, Biomedicines.

[3]  L. Birnbaumer,et al.  Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice , 2021, Hepatology.

[4]  E. Witkowski,et al.  Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity , 2021, Hepatology communications.

[5]  A. Shevchenko,et al.  Nonalcoholic fatty liver disease stratification by liver lipidomics , 2021, Journal of lipid research.

[6]  B. Finck,et al.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus , 2021, Nature Reviews Endocrinology.

[7]  S. Cockell,et al.  Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis , 2021, Hepatology.

[8]  C. Byrne,et al.  Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review , 2021, Diabetes, Obesity & Metabolism.

[9]  K. Hedfalk,et al.  LPIAT1/MBOAT7 contains a catalytic dyad transferring polyunsaturated fatty acids to lysophosphatidylinositol. , 2021, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[10]  J. Colca,et al.  Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide , 2021, The Journal of biological chemistry.

[11]  K. Clément,et al.  Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis , 2020, Science Translational Medicine.

[12]  Nicholette D. Palmer,et al.  rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis , 2020, Journal of hepatology.

[13]  Mingfeng Xia,et al.  Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver , 2020, Journal of lipid research.

[14]  E. Fauman,et al.  Insights into genetic variants associated with NASH-fibrosis from metabolite profiling , 2020, Human molecular genetics.

[15]  M. Rius,et al.  Identification of p115 as a novel ACSL4 interacting protein and its role in regulating ACSL4 degradation. , 2020, Journal of proteomics.

[16]  K. Huse,et al.  Loss of hepatic Mboat7 leads to liver fibrosis , 2020, Gut.

[17]  D. Ford,et al.  2-Chlorofatty acids are biomarkers of sepsis mortality and mediators of barrier dysfunction in rats[S] , 2020, Journal of Lipid Research.

[18]  J. Pihlajamäki,et al.  LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover , 2020, Gut.

[19]  N. Davidson,et al.  Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes , 2020, EBioMedicine.

[20]  Richard G. Lee,et al.  Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease , 2019, eLife.

[21]  A. Pujia,et al.  MBOAT7 is anchored to endomembranes by six transmembrane domains. , 2019, Journal of structural biology.

[22]  C. Löhr,et al.  Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice , 2019, PloS one.

[23]  J. Jelsing,et al.  Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[24]  B. Neuschwander‐Tetri,et al.  An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis , 2018, Hepatology communications.

[25]  Bo Wang,et al.  ER phospholipid composition modulates lipogenesis during feeding and in obesity. , 2017, The Journal of clinical investigation.

[26]  D. Samuel,et al.  Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients , 2017, Scientific Reports.

[27]  M. Orho-Melander,et al.  The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. , 2016, Journal of hepatology.

[28]  Dermot F. Reilly,et al.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.

[29]  D. Ma,et al.  Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n‐3 and n‐6 polyunsaturated fatty acids , 2015, Hepatology.

[30]  Eoin Fahy,et al.  Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S] , 2015, Journal of Lipid Research.

[31]  R. Kleemann,et al.  Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.

[32]  Jingwen Liu,et al.  Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation , 2014, Journal of Lipid Research.

[33]  S. Matsuda,et al.  LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is required for cortical lamination in mice , 2012, Molecular biology of the cell.

[34]  F. Kuypers,et al.  Mammalian Long-Chain Acyl-CoA Synthetases , 2008, Experimental biology and medicine.

[35]  A. Hamsten,et al.  Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects , 2007, Diabetes.

[36]  Michelle M Wiest,et al.  A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.